Cargando…

Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms

We used data from 852 consecutive subjects with myelodysplastic neoplasms (MDS) diagnosed according to the 2016 (revised 4th) World Health Organization (WHO) criteria to evaluate the 2022 (5th) edition WHO classification of MDS. 30 subjects previously classified as MDS with an NPM1 mutation were re-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yudi, Wu, Junying, Qin, Tiejun, Xu, Zefeng, Qu, Shiqiang, Pan, Lijuan, Li, Bing, Wang, Huijun, Zhang, Peihong, Yan, Xin, Gong, Jingye, Gao, Qingyan, Gale, Robert Peter, Xiao, Zhijian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712101/ https://www.ncbi.nlm.nih.gov/pubmed/36224330 http://dx.doi.org/10.1038/s41375-022-01718-7

Ejemplares similares

IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes
por: Wu, Junying, et al.
Publicado: (2022)

ASXL2 mutated myelodysplastic syndrome in a novel germline G6b variant
por: Qu, Shiqiang, et al.
Publicado: (2022)

VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder
por: Huang, Huijun, et al.
Publicado: (2021)

Case of cryptic TNIP1::PDGFRB rearrangement presenting with myelodysplastic syndrome achieved hematologic and cytogenetic remission with low-dose imatinib plus decitabine therapy
por: Qu, Shiqiang, et al.
Publicado: (2023)

Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre
por: Huang, Huijun, et al.
Publicado: (2020)

Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study
por: Hu, Naibo, et al.
Publicado: (2021)

Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression
por: Yan, Xin, et al.
Publicado: (2023)

RBC distribution width predicts thrombosis risk in polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms
por: Shi, Zhongxun, et al.
Publicado: (2022)

Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
por: Li, Bing, et al.
Publicado: (2017)

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

Colony-forming unit cell (CFU-C) assays at diagnosis: CFU-G/M cluster predicts overall survival in myelodysplastic syndrome patients independently of IPSS-R
por: Li, Bing, et al.
Publicado: (2016)

A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes
por: Feng, Gege, et al.
Publicado: (2016)

P1035: RING SIDEROBLASTS <15% WAS AN INDEPENDENT RISK FACTOR FOR MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM WITH SF3B1 MUTATION AND THROMBOCYTOSIS
por: LI, Fuhui, et al.
Publicado: (2023)

Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response
por: Luo, Xueping, et al.
Publicado: (2018)

Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins
por: Huang, Huijun, et al.
Publicado: (2023)

Conventional interferon-a 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center
por: Liu, Dan, et al.
Publicado: (2022)

Implications of the 5(th) Edition of the World Health Organization Classification and International Consensus Classification of Myeloid Neoplasm in Myelodysplastic Syndrome With Excess Blasts and Acute Myeloid Leukemia
por: Lee, Cheonghwa, et al.
Publicado: (2023)

An introduction to the WHO 5th edition 2022 classification of testicular tumours
por: Berney, Daniel M, et al.
Publicado: (2022)

Using and understanding medical statistics: 5(th), revised and extended edition
por: Sundaram, K. R.
Publicado: (2017)

Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization for detecting chromosome abnormalities in myelodysplastic syndromes: A retrospective study
por: Ai, Xiaofei, et al.
Publicado: (2021)

CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia
por: Cui, Yajuan, et al.
Publicado: (2014)

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
por: Alaggio, Rita, et al.
Publicado: (2022)

Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748
por: Alaggio, Rita, et al.
Publicado: (2023)

Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes
por: Wang, Jingya, et al.
Publicado: (2016)

What’s new in breast pathology 2022: WHO 5th edition and biomarker updates
por: Muller, Kristen, et al.
Publicado: (2022)

What’s new in kidney tumor pathology 2022: WHO 5th edition updates
por: Tretiakova, Maria
Publicado: (2022)

Special Announcement – Guidelines to the Practice of Anesthesia – Revised Edition 2022
por: Dobson, Gregory R.
Publicado: (2021)

Korean guidelines for postpolypectomy colonoscopic surveillance: 2022 revised edition
por: Kim, Su Young, et al.
Publicado: (2022)

Korean Guidelines for Postpolypectomy Colonoscopic Surveillance: 2022 revised edition
por: Kim, Su Young, et al.
Publicado: (2023)

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
por: Palomo, Laura, et al.
Publicado: (2021)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
por: Calvete, Oriol, et al.
Publicado: (2023)

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
por: Khoury, Joseph D., et al.
Publicado: (2022)

What’s new in hematopathology 2023: updates on mature T-cell neoplasms in the 5th edition of the WHO classification
por: Marques-Piubelli, Mario L., et al.
Publicado: (2023)

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
por: Wan, Ziqi, et al.
Publicado: (2020)

Biochemistry, 4th Edition
por: Janson, Chris
Publicado: (1995)

Neuroscience. 5th Edition
por: Gerhard, Danielle
Publicado: (2013)

Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review
por: Fontana, Diletta, et al.
Publicado: (2023)

CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis
por: Zhang, Xinmin, et al.
Publicado: (2022)

Influence of demethylation on regulatory T and Th17 cells in myelodysplastic syndrome
por: Jia, Xinyan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e68ur6nh90rcvnmlvt8msb02lv